Inhibitor of nuclear factor kappa-B kinase-interacting protein (IKBIP)

Inhibitor of nuclear factor kappa-B kinase-interacting protein (IKBIP, also known as IKIP) is an adaptor protein involved in the regulation of cell stress and inflammatory signaling. It acts as a direct target of p53, promoting apoptosis after cellular stress or DNA damage, and is also a negative regulator of the NF-κB pathway, acting by interfering with IKKα/β complex activation[1][3][7]. This dual role positions IKBIP at the crossroads of apoptosis and immune modulation. IKBIP has been implicated as a biomarker of poor prognosis in glioma and is being explored as a potential regulator of epithelial-mesenchymal transition (EMT) in tumors[1]. There are currently no approved drugs that directly target IKBIP; however, research into peptide-based inhibitors suggests it may have future therapeutic relevance in controlling inflammation and tumor progression[1].

Other names

IKBKB interacting proteinIKIPI kappa-B kinase-interacting proteinIKBKB-interacting proteinIKK-interacting proteinFLJ31051I kappa B kinase interacting proteinIKIP_HUMAN

no known drugs directly targeting IKBIP; research on peptide-based NF-κB pathway inhibition ongoing[1]